Foundry Networks reports
--4:30 pm - By Barbara C. Costanza
Foundry Networks (FDRY: news, msgs) posted fourth-quarter earnings of $21.5
million, or 17 cents a share, compared with the year-ago total of $15.5 million, or
12 cents a share. Analysts polled by First Call expected a profit of 12 cents a
share. Revenue reached $105 million, compared with $55.1 million in the
year-ago period. In addition, the company said revenue would be in the range of
$100 million to $110 million for the first quarter. As for the full-year of 2000, the
company expects $475 million to $525 million.
Aktie gewinnt stark.
CORRECTED - Amgen reports lower Q4 earnings,
Neupogen sales slip
(in Thousand Oaks, Calif. story headlined ``Amgen reports lower Q4 earnings, Neupogen
sales slip,'' please read in lede ``just missing analyst forecasts'' and in third paragraph ``Amgen said it earned 24 cents in the
quarter...,'' instead of ``Amgen said it earned 26 cents in the quarter,'' (corrects operating EPS figure, clarifies to show it missed
forecasts).
THOUSAND OAKS, Calif., Jan 24 (Reuters) - Biotechnology giant Amgen Inc. (NasdaqNM:AMGN - news) on Wednesday
reported lower fourth-quarter net income amid slower sales of its immunity-boosting drug Neupogen, just missing analyst
forecasts.
Amgen, based in Thousand Oaks, Calif., said fourth-quarter income fell to $211 million, or 19 cents a diluted share, including
charges, compared with year-earlier totals of $282 million, or 26 cents. Revenue rose to $951.4 million from $927 million in
the fourth quarter of 1999.
Verliert leicht
Wednesday January 24, 4:33 pm Eastern Time
Immunex reports higher Q4 profits, strong Enbrel sales
SEATTLE, Jan 24 (Reuters) - Drugmaker Immunex Corp. (NasdaqNM:IMNX - news) on
Wednesday its fourth quarter profits rose more than 200 percent, edging above Wall Street
forecasts, as sales of its flagship anti-arthritis treatment Enbrel climbed 65 percent.
The Seattle-based company said net income for the quarter reached $49.2 million, or 9 cents a share, up from $16.2 million, or
3 cents a share, in the same period a year ago.
Analysts polled by First Call/Thomson Financial had on average estimated quarterly profit at 8 cents a share.
Immunex said total revenues for the quarter rose to $250.7 million, from $162.6 million in the fourth quarter of 1999. Enbrel
sales rose to $194.1 million in the latest quarter, a gain of 65 percent over the same period in 1999 and 13 percent increase
over the third quarter of 2000.
Leichte Gewinne.
Veritas' Q4 results beat Street estimates
MOUNTAIN VIEW, Calif., Jan 24 (Reuters) - Data management software vendor Veritas
Software Corp. (NasdaqNM:VRTS - news) said on Wednesday that its fourth-quarter pro
forma results surpassed expectations as revenues grew 64 percent from the year-ago quarter.
For the quarter ended Dec. 31, the Mountain View, Calif. company posted pro forma income -- excluding purchase
accounting adjustments, of 19 per diluted share, or $83.9 million, to beat analysts' average forecast of 17 cents per share,
according to First Call/Thomson Financial.
The results surpassed those from the year-ago quarter, when the company posted pro forma earnings of $50.7 million, or 12
per diluted share.
Fourth quarter revenues were grew to $370.1 million from $226.2 million a year ago.
Veritas shares closed 15/16 lower at $104-1/16 before the company's results were announced. The stock was down 8 percent
on the year in 2000, but has rebounded by 20 percent this year, outpacing the Nasdaq Composite.
unverändert...
Gruß Dampf